contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
      researchContentUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


nightingale-health-possible-breakthrough-moves-further-away

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Head of Nordic ER Development, Analyst

Antti Luiro

Nightingale Health operates in the medical technology sector. The company specializes in the development of medical technology products. The product portfolio is broad and includes platforms and services within blood analysis that are used for disease prevention purposes. In addition to the main business, service and related ancillary services are also offered. The business is operated globally with the largest presence in Europe.

Inderes              Lääkinnällisen laitteen tiekartta Yhdysvaltojen markkinoille - Inderes    Menestys Yhdysvalloissa edellyttää onnistumisia useilla osaalueilla.

A recording of the event is also available:

Suna has been invited to New York by Google for Health                   LinkedIn              🚀 A few inspiring days in New York City last week.  I joined Google’s Check...    🚀 A few inspiring days in New York City last week.  I joined Google’s Check Up event and Partner Summit in NYC with our COO, Janna Ranta, and left with even stronger conviction about where healthcare is going.  Thank you to the Google for Health team...

I don’t want to be nosy. (However) I am. Could you shed any light (in the spirit of elaborating) on why you breathed a sigh of relief in a situation where I almost crapped my pants?

Yeah, Tuukka jumped straight onto Bioretec’s lists, and I breathed a sigh of relief at that point myself.

Although I was a long-time NGH believer, I have been shouting here about Tuukka Paavola’s suspicious, hasty departure from the CFO position as a red flag. The CEO’s icy “thanks… [expletive] for absolutely nothing” words didn’t ease my fears one bit. On the contrary. My worst-case scenario then was that Paavola would have had to do something so unethical within his role that he refused and chose to walk out, slamming the door instead. After mulling over that news for a long time, and with sales stalling (either Terveystalo or Moli-Sani or something else is lagging or stuck for some reason), and the share price sliding below 1.5 euros, I dumped 30% of my holdings at a loss. Only today (I’m sometimes slow, sometimes stupid, and often both) did it become clear to me, thanks to @Vino_Pino in the BRETEC thread, that Paavola has apparently been the CFO of that outfit for TWO MONTHS already. And as CFO, he is responsible for the ongoing and potentially future printing of 1.75 billion shares, which is going to take an incomprehensibly outrageous amount of ink. Paavola’s dramatic exit may, in the end, be a really good signal for NGH owners. Our Silver Lining. Today I bought back a small piece of my big panic sell—at the day’s peak price, of course. This stock is so tightly wound right now that it can’t even handle a lukewarm-neutral-positive LINKEDIN (seriously!) update without jumping a quick 10%. I’m still waiting for buying opportunities under 1 euro if announcements about concrete sales increases (or large contracts that take a long time to monetize) don’t start trickling in. And quite soon.

Indonesia in focus.                   LinkedIn              #sevenstonesmarketentryindonesia #asianinsiders #markkinavalinta...    Indonesian terveydenhuollon mittakaava on megalomaaninen – mitä suomalaisilla digiterveysratkaisuilla olisi tarjottavanaan?  Indonesian kansallinen sairausvakuutusjärjestelmä on yksi maailman suurimmista universaalin terveydenhuollon järjestelmistä....                             Results of the collaboration with Terveystalo.                   LinkedIn              #ennaltaehkäisy #työterveys #terveystalo | Ilse Rauhaniemi    🙌🏻 Juuri julkaistu Näin Suomi voi -aineistomme kertoo, että poissaolot ovat laskeneet kaikissa suurimmissa diagnoosiluokissa ja erityisesti pidemmät, vuoden aikana yhteensä yli 30 päivän poissaolot, ovat vähentyneet!  🎉 Pitkäjänteinen yhteistyö...

Nightingale Health

Nightingale’s H2 figures were weak throughout. The targets for the new fiscal year were also more conservative than our expectations and suggested that the potential for stronger growth is further...

<p>Nightingale’s H2 figures were weak throughout. The targets for the new fiscal year were also more conservative than our expectations and suggested that the potential for stronger growth is further down the road than we assumed. Therefore, we lowered our estimates considerably. In the short term, the high risks associated with the company's growth and valuation levels have realized and our views have been dramatically wrong. We still see preconditions for the company to achieve a significant commercial breakthrough with its technology in the future, but in the light of current information we do not expect any clear signs of this appearing in the next few years. We believe that the combination of slower growth and a highly cash-flow-negative development phase offers little critical short-term supporting points for valuation, especially in the current weakened capital market. </p> 

	2022	23e	24e
Revenue	2.2	2.9	4.8
growth-%	6.0 %	30.5 %	66.8 %
EBIT (adj.)	-11.1	-12.9	-11.7
EBIT-% (adj.)	-501.8 %	-447.9 %	-243.3 %
EPS (adj.)	-0.20	-0.22	-0.20
Dividend	0.00	0.00	0.00
Dividend %
P/E (adj.)	neg.	neg.	neg.
EV/EBITDA	3.9	neg.	neg.

Nightingale Health: Possible breakthrough moves further away

Login required

Key Estimate Figures30.09.2022

Forum discussions